Select your localized edition:

Close ×

More Ways to Connect

Discover one of our 28 local entrepreneurial communities »

Be the first to know as we launch in new countries and markets around the globe.

Interested in bringing MIT Technology Review to your local market?

MIT Technology ReviewMIT Technology Review - logo


Unsupported browser: Your browser does not meet modern web standards. See how it scores »

{ action.text }

Even though nearly 2,000 genetic tests are available today, most Americans have never taken one. (Save, perhaps, for newborn screening.) That may soon change, as the nation’s largest businesses responsible for managing prescription benefits, Medco and CVS Caremark, delve into the DNA testing business. Taken together, the two companies cover more than 100 million Americans.

In the industry’s jargon, Medco and CVS Caremark are known as pharmacy-benefit managers, acting as middlemen between insurers or employers and their customers or employees to negotiate cheaper drug prices, and to develop tools to improve the prescription process. These companies largely took over the prescription drug industry 15 years ago, and they may now do the same for genetic testing.

Earlier this month, Medco announced that it had acquired DNA Direct, a genetic testing startup based in San Francisco. The announcement follows a similar deal by CVS Caremark in December, when it increased its ownership share in Generation Health, a New Jersey-based startup created to analyze the effectiveness of genetic tests. “There is consumer demand right now,” says Robert Epstein, Medco’s chief medical officer. “People want to know–I’ve just been diagnosed with cancer, what tests do I need?”

While the majority of existing genetic tests screen for rare, single-gene disorders, a number are available for more common conditions–substantially increased risk for certain cancers, blood clots, or cardiac abnormalities, as well as genetically determined differences in an individual’s response to specific drugs. But use of the tests has not caught on, for a variety of reasons. Physicians don’t understand them, patients aren’t aware of them, and it’s not yet clear how effective they are at both improving a patient’s long-term outcome and decreasing health costs.

Medco is targeting all of those gaps. The company has already made some strides in pharmacogenomics–using genetic testing to personalize prescription drugs. Medco’s pharmacists call physicians and patients to offer the appropriate genetic test for a prescribed drug and then help interpret the results. “Physicians understand the concept of pharmacogenomics, but they don’t really feel comfortable interpreting the results,” says Pat Deverka, a physician and researcher at the Institute for Pharmacogenomics and Individualized Therapy at the University of North Carolina, in Chapel Hill. A recent survey by Medco found that while almost all physicians polled recognized that genetic profiles may influence a reaction to a drug, only 10 percent believed they were adequately informed about pharmacogenetic testing.

4 comments. Share your thoughts »

Credit: Technology Review

Tagged: Biomedicine, genetic testing, pharmacogenomics, prescription drugs

Reprints and Permissions | Send feedback to the editor

From the Archives


Introducing MIT Technology Review Insider.

Already a Magazine subscriber?

You're automatically an Insider. It's easy to activate or upgrade your account.

Activate Your Account

Become an Insider

It's the new way to subscribe. Get even more of the tech news, research, and discoveries you crave.

Sign Up

Learn More

Find out why MIT Technology Review Insider is for you and explore your options.

Show Me